HGH Fragment 176-191 and Tesamorelin Interaction

Monitor
Mechanism-based 47% confidence

HGH Fragment 176-191 and Tesamorelin have an interaction requiring monitoring for interaction with 47% confidence. Both HGH Fragment 176-191 and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

HGH Fragment 176-191

Growth Hormone Fragment | Fat Loss Peptide

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism.

Half-life: 15-20 minutes Typical dose: 250-500mcg weight loss, metabolic
carcinogenic riskinsulin disruptingteratogenic
View full profile

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Half-life: 26-38 minutes Typical dose: 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) growth hormone, weight loss
ghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pancreas
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (HGH Fragment 176-191, Tesamorelin). Monitor accordingly.
2x 2 compounds affect insulin sensitivity (HGH Fragment 176-191, Tesamorelin). Monitor fasting glucose and HbA1c.
2x 2 compounds share the teratogenic safety flag (HGH Fragment 176-191, Tesamorelin). Monitor accordingly.

Frequently Asked Questions

Can I take HGH Fragment 176-191 with Tesamorelin?

Yes, but with caution. Both HGH Fragment 176-191 and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is HGH Fragment 176-191 and Tesamorelin safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between HGH Fragment 176-191 and Tesamorelin?

Both HGH Fragment 176-191 and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time HGH Fragment 176-191 and Tesamorelin?

HGH Fragment 176-191 has a half-life of 15-20 minutes and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: HGH Fragment 176-191 vs Tesamorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.